Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment.

ABSTRACT:

Background

The p64MW HPC and p48MW HPC flow diverters have reduced thrombogenicity due to hydrophilic coating. The purpose of this study was to evaluate its safety and efficacy in Mongolian patients under single antiplatelet therapy (SAPT) with prasugrel.

Materials and methods

We performed a retrospective review of patients enrolled into our prospectively maintained database to identify all patients treated with either the p48MW HPC or p64MW HPC under SAPT. We recorded baseline demographics, aneurysm size and location, procedural complications, angiographic and clinical results.

Results

24 patients, (female = 21, 87.5%), age 48.2 ± 11.6 years (range 25-63) underwent treatment of 30 aneurysms with either p64MW HPC or p48MW HPC. All aneurysms were saccular with dome wid

SUBMITTER: Bhogal P 

PROVIDER: S-EPMC9178779 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature